Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Properties of Orally Administered APG-2575 in Patients With Hematologic Malignancies

NCT03913949 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT03913949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03913949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Properties of Orally Administered APG-2575 in Patients With Hematologic Malignancies
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 3, 2019
Completion date
December 31, 2026
Enrollment
74 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, non hodgkin lymphoma